[go: up one dir, main page]

AR100306A1 - Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia - Google Patents

Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia

Info

Publication number
AR100306A1
AR100306A1 ARP150100462A ARP150100462A AR100306A1 AR 100306 A1 AR100306 A1 AR 100306A1 AR P150100462 A ARP150100462 A AR P150100462A AR P150100462 A ARP150100462 A AR P150100462A AR 100306 A1 AR100306 A1 AR 100306A1
Authority
AR
Argentina
Prior art keywords
hypoglucemia
stable
treatment
glucagon analogs
glucagon
Prior art date
Application number
ARP150100462A
Other languages
English (en)
Inventor
Kresten Nielsen Peter
Kruse Thomas
F Lau Jesper
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR100306A1 publication Critical patent/AR100306A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Derivados de análogos de glucagón que comprenden las sustituciones Imp1 y His3, un sustituyente que tiene entre tres y diez porciones con carga negativa unidos de manera covalente a una cadena lateral de una lisina así como intermedios y composiciones de esta y para su uso en la medicina.
ARP150100462A 2014-02-18 2015-02-18 Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia AR100306A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14155497 2014-02-18

Publications (1)

Publication Number Publication Date
AR100306A1 true AR100306A1 (es) 2016-09-28

Family

ID=50112828

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100462A AR100306A1 (es) 2014-02-18 2015-02-18 Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia

Country Status (15)

Country Link
US (1) US9963496B2 (es)
EP (1) EP3107560A1 (es)
JP (1) JP2017509603A (es)
KR (1) KR20160114082A (es)
CN (1) CN106029088A (es)
AR (1) AR100306A1 (es)
AU (1) AU2015220909A1 (es)
BR (1) BR112016016321A2 (es)
CA (1) CA2939763A1 (es)
IL (1) IL246483A0 (es)
MX (1) MX2016010599A (es)
RU (1) RU2016134425A (es)
SA (1) SA516371639B1 (es)
TW (1) TW201613955A (es)
WO (1) WO2015124612A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961822A (zh) 2009-07-13 2015-10-07 西兰制药公司 酰化胰高血糖素类似物
EA028665B1 (ru) 2012-05-03 2017-12-29 Зилэнд Фарма А/С Соединения - двойные агонисты gip-glp-1 и способы
JP6534927B2 (ja) 2012-07-23 2019-06-26 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN119119233A (zh) 2013-10-17 2024-12-13 西兰制药公司 酰化胰高血糖素类似物
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
JP2017536343A (ja) 2014-10-10 2017-12-07 ノヴォ ノルディスク アー／エス 安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CA2674354A1 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
GEP20135944B (en) 2007-02-15 2013-10-25 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
TWI474832B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 胰高血糖素／ｇｌｐ-１受體共同激動劑
EP2307037A4 (en) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
WO2010096052A1 (en) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
RU2012101274A (ru) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения глюкагона, активные в отношении рецептора gip
CN104961822A (zh) 2009-07-13 2015-10-07 西兰制药公司 酰化胰高血糖素类似物
US20130035285A1 (en) 2010-03-26 2013-02-07 Novo Nordisk A/S Novel glucagon analogues
CA2830974A1 (en) 2011-03-28 2012-10-04 Jesper F. Lau Novel glucagon analogues
EP2718317B1 (en) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
EP2758426B1 (en) 2011-09-23 2019-08-07 Novo Nordisk A/S Novel glucagon analogues
WO2013167454A1 (en) * 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104583232B (zh) * 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物

Also Published As

Publication number Publication date
IL246483A0 (en) 2016-08-31
BR112016016321A2 (pt) 2017-10-03
EP3107560A1 (en) 2016-12-28
AU2015220909A1 (en) 2016-07-14
MX2016010599A (es) 2016-11-18
CN106029088A (zh) 2016-10-12
US20170008943A1 (en) 2017-01-12
SA516371639B1 (ar) 2018-10-25
RU2016134425A (ru) 2018-03-20
RU2016134425A3 (es) 2018-12-10
TW201613955A (en) 2016-04-16
CA2939763A1 (en) 2015-08-27
US9963496B2 (en) 2018-05-08
KR20160114082A (ko) 2016-10-04
WO2015124612A1 (en) 2015-08-27
JP2017509603A (ja) 2017-04-06

Similar Documents

Publication Publication Date Title
AR100306A1 (es) Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
MX2015003140A (es) Formulaciones de enzalutamida.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
PE20151023A1 (es) Triazolopirazinas
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CL2015002060A1 (es) Compuestos.
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2016014854A (es) Compuestos y composiciones para inducir condrogenesis.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
CL2018002368A1 (es) Formulaciones de oritavancina
GT201500124A (es) Forma sòlida de un derivado de dihidro-pirido-oxazina

Legal Events

Date Code Title Description
FB Suspension of granting procedure